9TMZ | pdb_00009tmz

Akt1 mutant in complex with the 1-isopropyl 1,5-substituted pyrazole containing compound


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 
    0.243 (Depositor), 0.243 (DCC) 
  • R-Value Work: 
    0.200 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 
    0.202 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9TMZ

Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history

Literature

Isoform-Selective Targeting of Akt Through Covalent Allosteric Inhibition.

D'Angelo, G.D.Pervanidis, K.A.Athanasiadis, I.Lukianchikov, V.Scrima, A.Depta, L.Stier, S.Muller, M.P.Farin, H.F.Quambusch, L.Rauh, D.

(2026) Angew Chem Int Ed Engl : e3567206-e3567206

  • DOI: https://doi.org/10.1002/anie.3567206
  • Primary Citation Related Structures: 
    9TMT, 9TMU, 9TMV, 9TMW, 9TMY, 9TMZ, 9TN0, 9TN1, 9TN2, 9TN3, 9TN4

  • PubMed Abstract: 

    The Akt family of serine/threonine kinases plays a crucial role in various cellular processes, including proliferation, survival, and metabolism. Three Akt isoforms (Akt1, Akt2, and Akt3) have distinct physiological roles, and while individual isoform dysregulation is disease-linked, unselective Akt inhibition leads to side effects. Here, we report the development of selective covalent-allosteric Akt inhibitors (CAAIs) targeting Akt2 and Akt3 while sparing Akt1. Guided by protein x-ray crystallography and molecular modeling, key structural differences within the allosteric pockets of the isoforms were identified and exploited in a structure-based design strategy. By stabilizing the inactive kinase conformation, CAAIs overcome the intrinsic selectivity limitations of ATP-competitive inhibitors. After biological characterization, the pyrazole-containing inhibitors emerged as the most potent and selective Akt2 inhibitors, while inhibitors with pyridines as an isoform-selective element were predominantly targeting Akt3 selectively. Importantly, these new inhibitors were also evaluated in patient-derived colorectal cancer organoids. Co-crystal structures of inhibitors bound to an engineered construct mimicking the Akt2 allosteric pocket elucidated the molecular basis of isoform selectivity, guiding further optimization. This work not only establishes a framework for the development of isoform-selective therapeutics but also highlights the potential for unraveling isoform-specific functions in signaling pathways relevant to cancer biology.


  • Organizational Affiliation
    • Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.

Macromolecule Content 

  • Total Structure Weight: 52.33 kDa 
  • Atom Count: 3,109 
  • Modeled Residue Count: 374 
  • Deposited Residue Count: 445 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
RAC-alpha serine/threonine-protein kinase445Homo sapiensMutation(s): 7 
Gene Names: AKT1PKBRAC
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for P31749 (Homo sapiens)
Explore P31749 
Go to UniProtKB:  P31749
PHAROS:  P31749
GTEx:  ENSG00000142208 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP31749
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1JW2
(Subject of Investigation/LOI)

Query on A1JW2



Download:Ideal Coordinates CCD File
B [auth A]~{N}-[2-oxidanylidene-3-[1-[[4-[3-phenyl-5-[(2-propan-2-ylpyrazol-3-yl)methyl]pyridin-2-yl]phenyl]methyl]piperidin-4-yl]-1~{H}-benzimidazol-5-yl]propanamide
C40 H43 N7 O2
IMSGIKAIRLIYPR-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free:  0.243 (Depositor), 0.243 (DCC) 
  • R-Value Work:  0.200 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 0.202 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.88α = 90
b = 71.32β = 107.26
c = 68.01γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other governmentNW21-062C
Other privateTACTIC
European Regional Development FundEuropean UnionEFRE-800400
German Research Foundation (DFG)Germany--

Revision History  (Full details and data files)

  • Version 1.0: 2026-09-16
    Type: Initial release